Self-management program for greater trochanteric pain syndrome

Self-management Program for Greater Trochanteric Pain Syndrome: a Randomized Controlled Trial

Not applicable Interventional Oslo University Hospital · NCT06297148

This study tests if a self-management program can help people with greater trochanteric pain syndrome feel better compared to regular care.

Quick facts

PhaseNot applicable
Study typeInterventional
Enrollment110 (estimated)
Ages18 Years to 70 Years
SexAll
SponsorOslo University Hospital Academic / other
Locations1 site (Oslo)
Trial IDNCT06297148 on ClinicalTrials.gov

What this trial studies

This study investigates the effectiveness of a self-management program compared to usual care for patients suffering from greater trochanteric pain syndrome (GTPS). Participants will be randomly assigned to either the self-management group or the usual care group, with follow-ups at 3, 6, and 12 months to assess pain and function. The study aims to determine not only the clinical effectiveness but also the cost-effectiveness of the self-management approach. This is the first study of its kind focusing on self-management strategies for GTPS, which is a common and debilitating condition.

Who should consider this trial

Good fit: Ideal candidates are individuals aged 18 to 70 with a history of lateral hip pain lasting more than 3 months and a pain intensity of at least 3 on a numeric rating scale.

Not a fit: Patients with significant back pain causing referred pain to the lateral hip may not benefit from this study.

Why it matters

Potential benefit: If successful, this study could provide patients with a more effective and cost-efficient way to manage their lateral hip pain.

How similar studies have performed: While studies have shown the effectiveness of exercise and education for GTPS, this specific approach to self-management is novel and has not been previously tested.

Eligibility criteria

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Participants between 18 and 70 years of age
* History of lateral hip pain \> 3 months
* Reported average pain intensity the last week ≥ 3 on a numeric rating scale
* Lateral hip pain is the main complaint
* Pain on palpation of the greater trochanter region
* In addition, lateral hip pain on at least one of the following tests:

  * Single leg stance test: standing 30 seconds on the affected leg
  * FADER: passive stretch/compression of gluteus medius/minimus
  * FADER-R: static muscle test with resistance to internal hip rotation
  * ADD: passive stretch to hip adduction in sidelying
  * ADD-R: resisted hip abduction in sidelying
  * FABER (Patrick's) test

A positive test is defined as a spontaneous reproduction of the participant's lateral hip pain. In participants with bilateral lateral hip pain, the worst hip will be included, and the presence of bilateral pain will be documented.

Exclusion Criteria:

* Significant back pain causing referred pain to the lateral hip
* Clinical signs of radiculopathy
* Symptomatic osteoarthritis
* Other hip joint pathologies
* History of trauma or surgery on the affected side
* Pregnancy or post-partum pelvic pain (under 12 months since birth)
* Active cancer
* Not able to write, read, and comprehend Norwegian (without the use of an interpreter)

Where this trial is running

Oslo

Study contacts

How to participate

  1. Review the eligibility criteria above with your treating physician.
  2. Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
  3. Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions GTPS - Greater Trochanteric Pain SyndromeGluteal TendinopathyTrochanteric BursitisLateral Hip PainGreater Trochanteric Pain SyndromeLateral hip painGluteal tendinopathyTrochanteric bursitis
Last reviewed 2026-06-09 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.